Society of Infectious Diseases Pharmacists | SAP Partner

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).

In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

In the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.

Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.

In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.

In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.

In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.

In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.

In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.

The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.

The latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.

How pharmacists can use shared decision-making to improve antibiotic use.

Introducing “Bench to Bedside With SIDP,” a new column covering everything from antimicrobial stewardship and pharmacokinetics/pharmacodynamics to mentorship, preceptorship, and more.

In part 2 of the interview, Ryan W. Stevens, PharmD, BCIDP, discusses the risks associated with convalescent plasma and highlights what clinicians should know.

In part 1 of our interview, Ryan W. Stevens, PharmD, BCIDP, provides an overview of how convalescent plasma has been used to treat infectious diseases including coronaviruses.

Jeannette Bouchard, PharmD, discusses how ID pharmacists are taking on new responsibilities and working collaboratively to respond to COVID-19.

Matthew Davis, PharmD, provides an overview on the agent remdesivir.

Thomas Dilworth, PharmD, provides a recap of ACEIs, ARBs, and NSAIDs in patients with COVID-19.

Krutika N. Mediwala, PharmD, BCPS, BCIDP, provides a recap of available information regarding Kaletra for the treatment of COVID-19.

COVID-19 does not present our first pandemic, nor will it be our last. What should we take note of?

Erin K. McCreary, PharmD, BCPS, BCIDP, discusses emerging literature on potential therapies COVID-19 and how the infectious disease community can work together during this pandemic.

Erin K. McCreary, PharmD, BCPS, BCIDP; and Jason M. Pogue, PharmD, BCPS, BCIDP, provide an update of published literature on experimental treatments for COVID-19 from the past week.

Just as influenza season started ramping up in the Northern Hemisphere, news hit the wire that Sanofi had secured over-the-counter rights for oseltamivir (Tamiflu).

Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.

The US Food and Drug Administration approved imipenem-cilastatin-relebactam to treat complicated intra-abdominal infections and complicated urinary tract infections in adults with limited treatment options.

When using ceftolozane/ tazobactam to treat patients with P aeruginosa respiratory tract infections, the use of extended or continuous antibiotic infusion and/or combination therapy with other active antibiotic agents should be considered, particularly if targeting higher MIC values.

Readmission rates for patients receiving OPAT are reported to be as high as 20%, mostly due to catheter-related problems, adverse drug reactions, or worsening of the primary infection.

This article evaluates the point in microbiological workup at which results of respiratory secretion and blood cultures could be interpreted as excluding MRSA and, thus, no longer warrant the empirical vancomycin therapy.

A recent study reported the benefit of vaginal microbiome transplantation for the treatment of recurrent bacterial vaginosis.